)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Spyre Therapeutics (SYRE) investor relations material
Spyre Therapeutics Stifel Virtual Immunology and Inflammation Forum summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Stifel Virtual Immunology and Inflammation Forum summary15 Sep, 2025
Strategic focus and clinical development
Targeting unmet needs in autoimmune diseases with two ongoing phase II trials, focusing on IBD and rheumatic diseases.
Utilizing co-formulated combinations of optimized antibodies against α4β7, TL1A, and IL-23 p19 to address multiple disease pathways.
Announced first dosing of anti-TL1A antibody in three rheumatic diseases, aiming for quarterly or twice-annual dosing.
Expecting nine proof-of-concept placebo-controlled readouts over the next two years, covering indications with over $60 billion in annual revenue.
Aggressive capital formation has secured funding for all planned readouts and operations into the second half of 2028.
Rationale for combination therapies and competitive landscape
Combination therapies in IBD are seen as the most promising way to break the efficacy ceiling, supported by studies like J&J's VEGA and AFFINITY.
VEGA showed nearly double the remission rate with combination therapy versus monotherapy in ulcerative colitis.
Co-formulation of antibodies is preferred over bispecifics due to lower immunogenicity risk, better target engagement, and flexible dosing ratios.
Small molecule orals are unlikely to match the efficacy of biologics or optimized antibody combinations.
The market favors long-acting injectables over daily orals if efficacy is similar.
Study design and upcoming milestones
SKYLINE platform study investigates three monotherapies and their combinations, with open-label Part A and placebo-controlled Part B.
Part A aims for early proof of concept, with results expected in 2026; Part B will provide six readouts in 2027.
Subcutaneous and IV dosing strategies are tailored to optimize induction and maintenance, especially for anti-IL-23 P19 antibody.
Open-label data will focus on objective disease improvement measures like endoscopy and histology.
Six readouts from both IBD and rheumatic disease studies are expected next year, with additional industry readouts anticipated.
How do Spyre's combos differentiate from bispecifics?
Address the chest tightness AE from TL1A Phase 1.
What is the commercial strategy for Skyway assets?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Spyre Therapeutics earnings date
Q3 20256 Nov, 2025
Next Spyre Therapeutics earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Spyre Therapeutics Inc., previously known as Aeglea BioTherapeutics, is a clinical-stage biotechnology company. It specializes in developing therapeutics for inflammatory bowel disease (IBD), which includes conditions like ulcerative colitis and Crohn's disease. The company's focus is on creating novel and proprietary monoclonal antibody product candidates designed to address unmet needs in IBD care. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage